Company overview

Novartis Ireland Limited is the Irish affiliate of Swiss-based Novartis AG – one of the largest pharmaceutical companies in the world. Novartis is one of Ireland’s leading employers in the healthcare industry. One of the first pharmaceutical companies to locate in Ireland in the 1950’s, Novartis has a strong history of investing in Ireland over the last sixty years.

Novartis currently employs approximately 1,100 people in Dublin. In March 2013, Novartis announced the establishment of a Global Business Services Center in Elm Park, Dublin. Novartis Innovative Medicines is also based in Elm Park. Novartis’ nationwide presence and hybrid working options means there are Novartis employees based all over Ireland.

≈190k

Patients supplied with Novartis medicines annually

#3

Market position (Rx) in Ireland

€295m

Value of Novartis' economic activity

Novartis has five healthcare priorities: Neuroscience, Cardiology, Immunology, Oncology and Hematology, with strong positions in tech platforms (eg cell & gene therapies). Novartis have a strong pipeline, with more than 160 products in clinical development. Novartis rank number five in Ireland in terms of number of clinical trials2*. Please see below an overview of the therapy areas in which we are currently working to develop products. For more information on our products, please go to www.medicines.ie

Reflecting our commitment to innovation, 18.5% of pharma net sales globally is invested back into research and development, focusing on the areas of greatest patient need and scientific promise1. Watch the video to see the impact of innovation and collaboration on patients’ lives in Ireland.


Find out more about our work in Ireland and what matters to us below

Novartis Commercial Operations at Elm Park

Health systems around the world, and in Ireland, are under pressure from the challenges of an aging population and managing chronic diseases. At Novartis Innovative Medicines we're working hard to address these issues and add value to the healthcare system through our range of medicines. As well as medicines, we are providing healthcare solutions “beyond the pill” that are fit for the future, for example new technologies, innovative devices, and patient-centric services. For example our Razorbill clinical trial, conceived in Ireland, but with sites across the globe, is assessing the use of artificial intelligence in reading scans of the eye in people with sight-threatening disease, in order to support treatment decisions, and improve outcomes for patients.

Novartis Corporate Center at Elm Park

The Novartis Corporate Center was set up in 2013. The center, one of six around the world, delivers a variety of services to Novartis globally.

Novartis Elm Park

The Novartis Corporate Center has a deep talent pool driving innovation, standardisation and world-class service delivery. There are currently approximately 1,000 associates employed at the site with >40 nationalities speaking 29 languages. Almost half of the associates are educated to master’s degree level while 17% hold a PhD.

 

Manufacturing at Ringaskiddy - Sterling Pharma Solutions

Novartis Ringaskiddy

In 2022, Novartis announced it had reached an agreement with Sterling Pharma Solutions (Sterling), a leading global development and manufacturing company, to divest Novartis Ringaskiddy Limited Pharmaceutical facility (NRL), located in Ringaskiddy in Ireland.

The Ringaskiddy Campus will continue to play an important role in producing medicine for Novartis (active pharmaceutical ingredient (API)). Sterling Pharma Solutions will produce Novartis API’s for cardiology, immunology and oncology medicines.  In 2022, the production facilities secured a 16 million US dollar investment from Novartis, to manufacture a significant cardiovascular medicine on the site.


We demonstrate our values through our actions

Novartis response to the coronavirus disease (COVID-19) pandemic

In the face of a global pandemic, Novartis has mobilized R&D capabilities, medicines, clinical trials expertise and aid, to provide support where we can.  Novartis, through its employees in Dublin and Cork, is supporting the fight against COVID-19. Below are just some of the ways in which we worked to support the healthcare system in 2020.1

50 000

Gloves donated

25 000

Masks donated

$40m

Novartis Covid Response Fund

4+

Projects from Ireland benefited

We partner with patient communities around Ireland to improve and extend people's lives

Read more about Novartis' societal impact in Ireland here.

Corporate Responsibility and working environment

We are committed to improving health through responsible business practices. A key part of that is our engagement with the wider community outside of Novartis and our volunteer activities. As well as this, we want to create an inclusive, supportive and empowering workplace for our teams, and are proud of our numerous employment awards.1

 

41%

Female Management. Goal: Gender parity by 2023

2022

Top Employer. Novartis Graduate Recruitment Program

Protecting the environment

We work to ensure that our business practices are environmentally friendly, minimizing their impact as much as possible. We have set ourselves ambitious environmental goals to meet in Ireland, which we are on our way to achieving. We aim to be carbon neutral and half our water consumption by 2025. Our Elm Park Campus is part of the All Ireland Pollinator Plan and we have the goal of having 75% of commercial materials digital in 2022. We also have a number of electric vehicle charging points on-site.

  1. Novartis Data on File
  2. Novartis Annual Review, 2020
  3. www.clinicaltrials.gov, Jan 2021